Solventum (SOLV) Stock Price, News & Analysis

Company Overview

Solventum Corporation (NYSE: SOLV) is a global healthcare company that develops products and solutions intended to improve patient care, support healthcare professionals and enhance the efficiency of healthcare systems. Its offerings serve hospitals, clinics, dental practices, laboratories, manufacturers and other healthcare-related organizations.

The company’s portfolio includes medical and surgical products such as wound-care systems, dressings, skin-protection products, sterilization assurance products and solutions used in operating rooms. Solventum also provides dental products, including restorative materials, adhesives, preventive-care products and digital dentistry solutions. In addition, its Health Information Systems business offers software and technology designed to support clinical documentation, coding, revenue-cycle management and other healthcare administrative functions.

Solventum also develops purification and filtration technologies used in healthcare, biopharmaceutical, industrial and other specialized applications. Its products and services are sold internationally, serving customers across North America, Europe, Asia and other global markets.

Solventum became an independent publicly traded company on April 1, 2024, following its separation from 3M. Bryan Hanson serves as the company’s president and chief executive officer.

Key Stats

• Today's Range: $85.18 to $89.00
• 50-Day Range: $84.08 to $92.44
• 52-Week Range: $62.38 to $94.16
• Volume: 1.17 million shs
• Average Volume: 915,572 shs
• Market Capitalization: $14.60 billion
• P/E Ratio: 10.48
• Dividend Yield: N/A
• Price Target: $92.80
• Consensus Rating: Moderate Buy

Solventum Stock Analysis - MarketRank™

Solventum scored higher than 44% of companies evaluated by MarketBeat, and ranked 616th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Solventum has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 10 buy ratings, 3 hold ratings, and 1 sell rating.

Upside/Downside

The consensus price target for Solventum is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Solventum has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 0.14%

Earnings Growth

Earnings for Solventum are expected to grow by 0.14% in the coming year, from $7.22 to $7.23 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Solventum is 10.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.72.

Price to Earnings Ratio vs. Sector

The P/E ratio of Solventum is 10.48, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.28.

Price to Earnings Growth Ratio

Solventum has a PEG Ratio of 1.32. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Solventum has a P/B Ratio of 2.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.88% of the float of Solventum has been sold short.

Short Interest Ratio / Days to Cover

Solventum has a short interest ratio ("days to cover") of 5.43.

Change versus previous month

Short interest in Solventum has recently increased by 0.66%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Solventum does not currently pay a dividend.

Dividend Growth

Solventum does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.26

News Sentiment

Solventum has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Solventum this week, compared to 5 articles on an average week.

Search Interest

Only 4 people have searched for SOLV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

6 people have added Solventum to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Solventum insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.24% of the stock of Solventum is held by insiders.

Percentage Held by Institutions

Solventum has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/19/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NYSE:SOLV
• Previous Symbol: NYSE:SOLV
• CIK: 1964738
• Web: www.solventum.com
• Phone: 651-733-1110
• Fax: N/A
• Employees: 20,000
• Year Founded: 2023

Price Target and Rating

• Average Price Target for Solventum: $92.80
• High Price Target: $113.00
• Low Price Target: $60.00
• Potential Upside/Downside: +8.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.18
• Trailing P/E Ratio: 10.48
• Forward P/E Ratio: 11.88
• P/E Growth: 1.32
• Net Income: $1.56 billion
• Net Margins: 17.26%
• Pretax Margin: 20.41%
• Return on Equity: 25.09%
• Return on Assets: 8.78%

Debt

• Debt-to-Equity Ratio: 1.00
• Current Ratio: 1.02
• Quick Ratio: 0.74

Sales & Book Value

• Annual Sales: $8.33 billion
• Price / Sales: 1.75
• Cash Flow: $8.98 per share
• Price / Cash Flow: 9.55
• Book Value: $29.11 per share
• Price / Book: 2.95

Miscellaneous

• Outstanding Shares: 170,220,000
• Free Float: 169,815,000
• Market Cap: $14.60 billion
• Optionable: Optionable
• Beta: 0.63